Thyroid-stimulating antibodies in patients with long-term remission of Graves' hyperthyroidism
- 1 October 1986
- journal article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 64 (21) , 1097-1100
- https://doi.org/10.1007/bf01726868
Abstract
The persistence of TSH receptor antibodies in Graves' disease despite the remission of hyperthyroidism has been described. Our study was designed to evaluate whether this extends to functionally active stimulators of the thyroid, since the occurrence of thyroid-stimulating antibodies (TSAb) in a euthyroid patient could well have important implications on our understanding of the pathogenetic role of such autoantibodies. Forty-four patients with a previous history of Graves' hyperthyroidism were reexamined after having been in long-lasting remission for 3 to 35 years (mean 8 years). Of the patients 16 had been treated by radioiodine, 17 by surgery, and 11 exclusively by antithyroid drugs. The determination of TSAb was based on T3 release from thyroid tissue in vitro to document the final response to these immunoglobulins. TSH-binding inhibiting immunoglobulins (TBII) were evaluated by a radioreceptor assay. TSAb were highly elevated in three of the 44 patients. These three patients showed a normal TSH response to i.v. TRH, suffered from endocrine ophthalmopathy, and had been treated by radioiodine for hyperthyroidism. TBII were found positive in seven patients including the three patients mentioned. The majority of patients positive for TSAb or TBII had been treated by radioiodine and none exclusively by antithyroid drugs. In conclusion, not only TBII but also T3 release-stimulating antibodies may occur in a minority of patients with long-term remission of Graves' hyperthyroidism. However, an absence of hyperthyroidism in these patients despite the presence of such thyroid stimulators seems to be only possible in association with a lack of functional responsiveness of the target organ due to previous administration of destructive therapies. Moreover, a major role of TBII in the absence of TSAb representing stimulatory inactive autoantibodies to the maintenance of remission was not apparent.Keywords
This publication has 17 references indexed in Scilit:
- Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' diseaseJournal of Molecular Medicine, 1985
- Methodische Probleme und klinische Wertigkeit der Bestimmung von TSH-Rezeptor-Antikörper mit einem kommerziellen KITJournal of Laboratory Medicine, 1985
- Thyroid Stimulating Immunoglobulins in Patients in Long-Term Remission after Graves' DiseaseHormone and Metabolic Research, 1984
- THYROID STIMULATING ANTIBODIES: AN AID TO THE STRATEGY OF TREATMENT OF GRAVES' DISEASE?Clinical Endocrinology, 1984
- Isolation of thyroid stimulating immunoglobulins by affinity chromatography using protein A sepharoseActa Endocrinologica, 1984
- Monoclonal antibodies to the thyrotropin receptor: stimulating and blocking antibodies derived from the lymphocytes of patients with Graves disease.Proceedings of the National Academy of Sciences, 1982
- AN IMPROVED RADIORECEPTOR ASSAY FOR TSH RECEPTOR ANTIBODIESClinical Endocrinology, 1982
- EFFECT OF RADIOIODINE ON STIMULATORY ACTIVITY OF GRAVES’IMMUNOGLOBULINSClinical Endocrinology, 1982
- INFLUENCE OF TREATMENT WITH RADIOIODINE AND PROPYLTHIORACIL ON THYROID STIMULATING IMMUNOGLOBULINS IN GRAVES' DISEASEClinical Endocrinology, 1980
- PREDICTION OF RELAPSE IN HYPERTHYROID GRAVES' DISEASEThe Lancet, 1980